Boston Scientific reported today its Q2 2020 results which show a very sharp decline in earnings due to the impact of the Covid-19 pandemic. Specifically for the active implantables industry, CRM dropped from $498M in Q2 2019 to $351M this quarter (-29.4%), and likewise neuromodulation dropped from $204M to $122M (-40%).